bendamustine hydrochloride has been researched along with Leukemia, Prolymphocytic, T-Cell in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diaz-Perez, J; Ingrasci, G; Romanelli, P; Verne, S; Yosipovitch, G | 1 |
| Al-Rohil, RN; Kheterpal, MK; Leckey, BD; Selim, MA | 1 |
| Abdeldayem, A; Aittokallio, T; Bhatti, MN; Bukhari, S; de Araujo, ED; Gawel, JM; Geletu, M; Gunning, PT; Hassan, MM; Herling, M; Ianevski, A; Israelian, J; Krämer, OH; Manaswiyoungkul, P; Moriggl, R; Mustjoki, S; Nawar, N; Neubauer, HA; Olaoye, OO; Radu, TB; Raouf, YS; Sedighi, A; Shouksmith, AE; Sorger, H; Timonen, S; Toutah, K; von Jan, J | 1 |
| Betrian, S; Bouabdallah, K; Cazin, B; Damaj, G; Debarri, H; Facon, T; Genet, P; Guidez, S; Herbaux, C; Leleu, X; Morschhauser, F; Pignon, JM; Ysebaert, L | 1 |
| Linn, YC; Ong, KH; Tan, D; Yong, HX | 1 |
5 other study(ies) available for bendamustine hydrochloride and Leukemia, Prolymphocytic, T-Cell
| Article | Year |
|---|---|
Cutaneous Presentation of T-Cell Prolymphocytic Leukemia Mimicking Dermatomyositis.
Topics: Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Biopsy; Dermatomyositis; Diagnosis, Differential; Female; Humans; Leukemia, Prolymphocytic, T-Cell; Middle Aged; Predictive Value of Tests; Skin Neoplasms; Stem Cell Transplantation; Treatment Outcome | 2021 |
Cutaneous involvement by T-cell prolymphocytic leukemia presenting as livedoid vasculopathy.
Topics: Aged; Alemtuzumab; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bendamustine Hydrochloride; Biopsy; Diagnosis, Differential; Disease Progression; Exanthema; Extremities; Fatal Outcome; Humans; Hyperpigmentation; Immunohistochemistry; Leukemia, Prolymphocytic, T-Cell; Male; Skin Neoplasms; Torso; Vascular Diseases | 2021 |
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Prolymphocytic, T-Cell; Male; Mice; Molecular Docking Simulation; Molecular Structure; para-Aminobenzoates; Pyrrolidines; Structure-Activity Relationship; Sulfonamides | 2021 |
Bendamustine is effective in T-cell prolymphocytic leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Evaluation; Female; Humans; Kaplan-Meier Estimate; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Retrospective Studies; Treatment Outcome | 2015 |
Chemoimmunotherapy with bendamustine hydrochloride and alemtuzumab demonstrates synergism in T-prolymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Synergism; Female; Humans; Immunotherapy; Leukemia, Prolymphocytic, T-Cell; Middle Aged; Nitrogen Mustard Compounds; Tumor Cells, Cultured | 2012 |